Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bendamustine - Eagle Pharmaceuticals

Next Previous
Drug Profile

Bendamustine - Eagle Pharmaceuticals

Alternative Names: BELRAPZO; Bendamustine 500mL; Bendamustine 50mL; Bendamustine hydrochloride - Eagle Pharmaceuticals; Bendamustine hydrochloride ready-to-dilute; Bendamustine hydrochloride RTD; Bendamustine II; Bendamustine rapid infusion; Bendamustine RI; Bendamustine RTD; Bendamustine shorter-infusion; Bendeka; Bendeka® rapid infusion; EP-3101; EP-3102; RTD bendamustine; TREAKISYM; Treakisym; TREAKISYM® ready-to-dilute liquid formulation; TREAKISYM®rapid infusion

Latest Information Update: 23 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eagle Pharmaceuticals
  • Developer Eagle Pharmaceuticals; SymBio Pharmaceuticals
  • Class Antineoplastics; Benzimidazoles; Butyric acids; Nitrogen mustard compounds; Nitrosourea compounds; Small molecules
  • Mechanism of Action Alkylating agents; Antimetabolites; DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • No development reported Solid tumours

Most Recent Events

  • 18 Jan 2024 Eagle Pharmaceuticals has patent protection for Bendamustine in USA
  • 17 Jan 2024 Eagle files lawsuits referencing bendamustine marketed by Slayback, Apotex, and Baxter each infringe one or more claims of the newly issued patents and requesting damages for any infringing sales of the respective accused products
  • 25 May 2023 Chemical structure information added

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top